Skip to content

Early Metabolic Resuscitation for Septic Shock

Early Metabolic Resuscitation: A Potential Solution to Multi-Organ Dysfunction Syndrome in Septic Shock

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03895853
Enrollment
2
Registered
2019-03-29
Start date
2019-10-04
Completion date
2020-05-04
Last updated
2024-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Organ Failure, Septic Shock, Severe Sepsis

Brief summary

This phase II trial studies how well early metabolic resuscitation therapy works in reducing multi-organ dysfunction in patients with septic shock. Early metabolic resuscitation is made of large doses of glucose, protein, and essential metabolic molecules that may help lower the effects of septic shock on the body. Giving patients early metabolic resuscitation in combination with standard of care may work better in reducing multi-organ dysfunction syndrome in patients with septic shock compared to standard of care alone.

Detailed description

PRIMARY OBJECTIVES: I. To assess the efficacy of administering early metabolic resuscitation with standard of care (SC + EMR) in patients diagnosed with septic shock for reducing 28-day mortality versus using the standard of care alone (SC). SECONDARY OBJECTIVES: I. To assess whether early metabolic resuscitation with standard of care (SC + EMR) is an effective strategy to reduce intensive care unit (ICU) mortality, hospital mortality, and 90-day mortality of septic shock patients relative to SC. II. To compare the time to death from any cause between patients administered SC + EMR versus SC after being diagnosed with septic shock. III. To assess whether SC + EMR is an effective strategy to reduce complications of septic shock such as: i) acute kidney injury, ii) dialysis requirements, iii) need for cardiovascular support or days on vasopressors, iv) need for invasive ventilation, days on ventilator support, v) duration of ICU stay, and vi) duration of hospital stay versus SC. IV. To describe the presence of any adverse effects between the two study groups (SC + EMR group versus \[vs\] SC group); thus, characterizing their safety. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I: Patients receive standard of care for septic shock. GROUP II: Patients receive standard of care treatment for septic shock and early metabolic resuscitation (IV) over continuous infusion for up to 7 days.

Interventions

OTHERBest Practice

Receive standard of care

DIETARY_SUPPLEMENTearly metabolic resuscitation

Given Intravenous

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
M.D. Anderson Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Admitted to the adult medical intensive care unit (MICU). * Diagnosis of septic shock within 12 hours of ICU admission defined as meeting criteria for sepsis in addition to the following: A) Vasopressor therapy needed to elevate mean arterial pressure (MAP) \>= 65 mmg Hg. B) Lactate \> 2 mmol/L (18 mg/dL) after adequate fluid resuscitation. * Sequential Organ Failure Assessment (SOFA) score meeting the following requirements A) Cardiovascular SOFA \>= 2 B) Total SOFA score =\< 12. * Patients meeting the above and not able to tolerate enteral nutrition above 70% of their estimated daily caloric need.

Exclusion criteria

* Do not resuscitate (DNR). * Comfort care and end-of-life patients. * Patients with SOFA scores greater than 12. * Pregnant women. * Jehovah Witnesses that do not accept albumin. * Active bleeding (e.g., gastrointestinal bleeding). * Acute neurological syndromes (e.g., stroke, hemorrhage, etc.). * End-stage renal disease (ESRD). * Chronic liver disease * Child-Pugh class C * Diagnosis of cirrhosis * Heart rate less than 50 beats per minute (bpm). * Respiratory rate less than 8 respirations per minute (rpm). * Temperature less than 95 degrees Fahrenheit (F) or 35 degrees Celsius (C). * Tumor lysis syndrome. * Sulfite allergy: amino acids administration are contraindicated. It is more common in steroid dependent asthmatics. (Please note that this is NOT sulfa allergy and is NOT contraindicated patients with sulfa allergy). Sulfites are present in dried fruits, beer, wines, sausages, jams, maple syrup, and many other food products. * Serum sodium concentration \< 130 mEq/L or \> 150 mEq/L (Note: Once serum sodium levels are \>= 130 or =\< 150 mEq/L within 12 hours after meeting inclusion criteria, the patient can then be considered for the study. This is only a temporary restriction. * Serum creatinine level: Serum creatinine (SCr) \> 2.5 mg/dL (Note: Once serum creatinine levels are =\< 2.5 mg/dL within 12 hours after meeting inclusion criteria, the patient can then be considered for the study. This is only a temporary restriction). * Urine output \< 400 cc/24 hours (hrs) plus creatinine \> 2.5 mq/dl (Note: Once urine output levels are \>= 400 cc within 12 hours after meeting inclusion criteria, the patient can then be considered for the study. This is only a temporary restriction). * Hyperkalemia K \> 5.5 mEq/L (Note: Once potassium levels are =\< 5.5 mEq/L within 12 hours after meeting inclusion criteria, the patient can then be considered for the study. This is only a temporary restriction). * Hyperglycemia: Glucose \> 250 mg/dL (Note: Once glucose is below 250 mg/dL within 12 hours after meeting inclusion criteria, the patient can then be considered for the study. This is only a temporary restriction.) * Hyperphosphatemia: Serum phosphorous \> 5.5 mg/dL. * Patient with a history of metabolic abnormality in any one of the following amino acids: alanine, arginine, cysteine hydrochloride, glycine, histidine, isoleucine, leucine, lysine acetate, methionine, phenylalanine, phosphoric acid, proline, serine, threonine, tryptophan, and valine.

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With 28-day Mortalityup to 28 days or until death, whichever comes firstTo assess the efficacy of administering Early Metabolic Resuscitation with Standard of Care (SC + EMR) in patients diagnosed with septic shock for reducing 28-day mortality versus using the Standard of Care alone (SC). Twenty-eight day mortality is defined during the time from the day SC+EMR or SC was first administered until a patient dies or is followed through 28 days (whichever comes first).

Secondary

MeasureTime frameDescription
Number of Participants With 90-Day Mortalityup to 90 days or until death, whichever comes firstTo assess whether Early Metabolic Resuscitation with standard of care (SC + EMR) is an effective strategy to reduce ICU mortality, hospital mortality, and 90-day mortality of septic shock patients relative to SC. ICU mortality is defined as mortality at ICU discharge relative to SC.
Number of Participants With Hospital Mortalityup to 90 days or until death, whichever comes firstTo assess whether Early Metabolic Resuscitation with standard of care (SC + EMR) is an effective strategy to reduce hospital mortality of septic shock patients relative to SC.
Number of Participants With ICU Mortalityup to 90-days or until death, whichever comes firstTo assess whether Early Metabolic Resuscitation with standard of care (SC + EMR) is an effective strategy to reduce ICU mortality of septic shock patients relative to SC. ICU mortality is defined as mortality at ICU discharge relative to SC.

Countries

United States

Participant flow

Recruitment details

Recruitment Period: November 2019- December 2019

Participants by arm

ArmCount
Intervention Group (EMR Solution)
Standard of care + Early metabolic resuscitation
0
Controlled Group (Standard Care)
Received standard of care alone
2
Total2

Baseline characteristics

CharacteristicControlled Group (Standard Care)TotalIntervention Group (EMR Solution)
Age, Categorical
<=18 years
0 Participants0 Participants
Age, Categorical
>=65 years
1 Participants1 Participants
Age, Categorical
Between 18 and 65 years
1 Participants1 Participants
Age, Continuous52 years52 years
Cancer stage
Localized/Locally advanced
1 Participants1 Participants0 Participants
Cancer stage
Metastatic Stage
0 Participants0 Participants0 Participants
Cancer Type
Breast
0 Participants0 Participants0 Participants
Cancer Type
Gastrointestinal
0 Participants0 Participants0 Participants
Cancer Type
Lung
1 Participants1 Participants0 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
2 Participants2 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants
Race (NIH/OMB)
Black or African American
1 Participants1 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants
Race (NIH/OMB)
White
1 Participants1 Participants
Region of Enrollment
United States
2 participants2 participants
Sex: Female, Male
Female
0 Participants0 Participants
Sex: Female, Male
Male
2 Participants2 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 00 / 2
other
Total, other adverse events
0 / 00 / 2
serious
Total, serious adverse events
0 / 02 / 2

Outcome results

Primary

Number of Participants With 28-day Mortality

To assess the efficacy of administering Early Metabolic Resuscitation with Standard of Care (SC + EMR) in patients diagnosed with septic shock for reducing 28-day mortality versus using the Standard of Care alone (SC). Twenty-eight day mortality is defined during the time from the day SC+EMR or SC was first administered until a patient dies or is followed through 28 days (whichever comes first).

Time frame: up to 28 days or until death, whichever comes first

Population: No participants participated in the Intervention group.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Intervention Group (EMR Solution)Number of Participants With 28-day Mortality0 Participants
Controlled Group (Standard Care)Number of Participants With 28-day Mortality0 Participants
Secondary

Number of Participants With 90-Day Mortality

To assess whether Early Metabolic Resuscitation with standard of care (SC + EMR) is an effective strategy to reduce ICU mortality, hospital mortality, and 90-day mortality of septic shock patients relative to SC. ICU mortality is defined as mortality at ICU discharge relative to SC.

Time frame: up to 90 days or until death, whichever comes first

Population: No participants participated in the Intervention group.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Intervention Group (EMR Solution)Number of Participants With 90-Day Mortality0 Participants
Controlled Group (Standard Care)Number of Participants With 90-Day Mortality0 Participants
Secondary

Number of Participants With Hospital Mortality

To assess whether Early Metabolic Resuscitation with standard of care (SC + EMR) is an effective strategy to reduce hospital mortality of septic shock patients relative to SC.

Time frame: up to 90 days or until death, whichever comes first

Population: No participants participated in the Intervention group.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Intervention Group (EMR Solution)Number of Participants With Hospital Mortality0 Participants
Controlled Group (Standard Care)Number of Participants With Hospital Mortality0 Participants
Secondary

Number of Participants With ICU Mortality

To assess whether Early Metabolic Resuscitation with standard of care (SC + EMR) is an effective strategy to reduce ICU mortality of septic shock patients relative to SC. ICU mortality is defined as mortality at ICU discharge relative to SC.

Time frame: up to 90-days or until death, whichever comes first

Population: No participants participated in the Intervention group.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Intervention Group (EMR Solution)Number of Participants With ICU Mortality0 Participants
Controlled Group (Standard Care)Number of Participants With ICU Mortality0 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026